Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000328:Adult; D000707:Anaphylaxis / Q000209:etiology; D000818:Animals; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006736:Horses; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D007165:Immunosuppression Therapy; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology*; D010689:Phlebitis / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012713:Serum Sickness / Q000209:etiology; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D001379:Azathioprine; D011241:Prednisone